Characterization of polyclonal antibodies raised against a linear peptide determinant of desmoglein-3

Journal of Experimental Therapeutics and Oncology

Volumn 5, Issue 1, 2005, Pages 1-7

  Angelini, Giovanni ^a   Bonamonte, Domenico ^a   Lin, Mong Shang ^b   Lucchese, Alberta ^a   Mittelman, Abraham ^c   Serpico, Rosario ^a   Simone, Simone ^a   Sinha, Animesh A ^d   Kanduc, Darja ^a  

^a UNIVERSITY OF BARI   (Italy)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Desmoglein 3; Low similarity sequence; Pemphigus vulgaris; Peptide Immunotherapy; Proteomics

Indexed keywords

ANTIGEN; DESMOGLEIN 3; PEPTIDE; POLYCLONAL ANTIBODY; PROTEOME;

AMINO ACID SEQUENCE; ANIMAL TISSUE; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOTHERAPY; MOUSE; NEWBORN; NONHUMAN; PATHOGENICITY; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; SEQUENCE HOMOLOGY;

ANIMALS; ANTIBODIES; DESMOGLEINS; HUMANS; IMMUNIZATION, PASSIVE; MICE; MICE, INBRED BALB C; PARANEOPLASTIC SYNDROMES; PEMPHIGUS; SKIN;

EID: 23044474907     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Wraith, D.C., Smilek, D.E., Mitchell, D.J., Steinman, L., and McDevitt, H.O. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. Cell. 59: 247-255, 1989.
2. Davis, C.B., Buerstedde, J.M., McKean, D.J., Jones, P.P., McDevitt, H.O., and Wraith, D.C. The role of polymorphic I-Ak beta chain residues in presentation of a peptide from myelin basic protein. J. Exp. Med. 169: 2239-2244, 1989.
3. Smilek, D.E., Wraith, D.C., Hodgkinson, S., Dwivedy, S., Steinman, L., and McDevitt, H.O. A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U.S.A. 88: 9633-9637, 1991.
4. Atkinson, M.A., Maclaren, N.K., and Luchetta, R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes. 39: 933-937, 1990.
5. Zhang, Z.J., Davidson, L., Eisenbarth, G., and Weiner, H.L. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc. Natl. Acad. Sci. U.S.A. 88: 10252-10256, 1991.
6. Muir, A., Peck, A., Clare-Salzler, M., Song, Y.H., Cornelius, J., Luchetta, R., Krischer, J., and Maclaren, N. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription. J. Clin. Invest. 95: 628-634, 1995.
7. Daniel, D., and Wegmann, D.R. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc. Natl. Acad. Sci. U.S.A. 93: 956-960, 1996.
8. Dikopoulos, N., Riedl, P., Schirmbeck, R., and Reimann, J. Novel peptide-based vaccines efficiently prime murine "help"-independent CD8+ T cell responses in the liver. Hepatology. 40: 300-309, 2004.
9. Kran, A.M., Sorensen, B., Nyhus, J., Sommerfelt, M.A., Baksaas, I., Bruun, J.N., and Kvale, D. HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). AIDS. 18: 1875-1883, 2004.
10. Elsawa, S.F., Rodeberg, D.A., and Celis, E. T-cell epitope peptide vaccines. Expert Rev. Vaccines. 3: 563-575, 2004.
11. Bocchia, M., Gentili, S., Abruzzese, E., Fanelli, A., Iuliano, F., Tabilio, A., Amabile, M., Forconi, F., Gozzetti, A., Raspadori, D., Amadori, S., and Lauria, F. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet. 365: 657-662, 2005.
12. Akiyama, Y., Tanosaki, R., Inoue, N., Shimada, M., Hotate, Y., Yamamoto, A., Yamazaki, N., Kawashima, I., Nukaya., I., Takesako, K., Maruyama, K., Takaue, Y., and Yamaguchi, K. Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. J. Transl. Med. 3: 4, 2005.
13. Wagner, S., Hafner, C., Allwardt, D., Jasinska, J., Ferrone, S., Zielinski, C.C., Scheiner, O., Wiedermann, U., Pehamberger, H., and Breiteneder, H. Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J. Immunol. 174: 976-982, 2005.
14. Gritzapis, A.D., Perez, S.A., Baxevanis, C.N., and Papamichail, M. Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo. Br. J. Cancer. 92: 72-79, 2005.
15. de Weck, A.L. Drug allergy, immunotherapy, immune complexes and anaphylaxis. Curr. Opin. Immunol. 2: 548-557, 1989.
16. McDevitt, H. Specific antigen vaccination to treat autoimmune disease. Proc. Natl. Acad. Sci. U.S.A. 101: 14627-14630, 2004.
17. Olszewska, W., and Steward, M.W. The molecular basis of the antigenic cross-reactivity between measles and cowpea mosaic viruses. Virology. 310: 183-189, 2003.
18. Vermont, C.L., van Dijken, H.H., Kuipers, A.J., van Limpt, C.J., Keijzers, W.C., van der Ende, A., de Groot, R., van Alphen, L., and van den Dobbelsteen, G.P. Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine. Infect. Immun. 71: 1650-1655, 2003.
19. Chiou, Y.H., You, C.Y., Wang, L.Y., van Limpt, C.J., Keijzers, W.C., van der Ende, A., de Groot, R., van Alphen, L., and van den Dobbelsteen, G.P. Detection of cross-reactivity for atopic immunoglobulin E against multiple allergens. Clin. Diagn. Lab. Immunol. 10: 229-232, 2003.
20. Shi, S., Ciurli, C., Cartman, A., Pidoux, I., Poole, A.R., and Zhang, Y. Experimental immunity to the G1 domain of the proteoglycan versican induces spondylitis and sacroiliitis, of a kind seen in human spondylarthropathies. Arthritis Rheum. 48: 2903-2915, 2003.
21. Gordon, T.P., Kinoshita, G., Cavill, D., Keech, C., Farris, A., Kaufman, K., McCluskey, J., and Purcell, A. Restricted specificity of intermolecular spreading to endogenous La (SS-B) and 60 kDa Ro (SS-A) in experimental autoimmunity. Scand. J. Immunol. 56: 168-173, 2002.
22. Eivazova, E.R., McDonnell, J.M., Sutton, B.J., and Staines, N.A. Cross-reactivity of antiidiotypic antibodies with DNA in systemic lupus erythematosus. Arthritis Rheum. 43: 429-439, 2000.
23. Natale, C., Giannini, T., Lucchese, A., and Kanduc, D. Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences. Immunol. Cell Biol. 78: 580-585, 2000.
24. Kanduc, D., Lucchese, A., and Mittelman, A. Individuation of monoclonal anti-HPV16 E7 antibody linear peptide epitope by computational biology. Peptides. 22: 1981-1985, 2001.
25. Mittelman, A., Lucchese, A., Sinha, A.A., and Kanduc, D. Monoclonal and polyclonal humoral immune response to EC HER-2/neu peptides with low similarity to the host's proteome. Int. J. Cancer. 98: 741-747, 2002.
26. Lucchese, A., Stevanovic, S., Sinha, A.A., Mittelman, A., and Kanduc, D. Role of MHC II affinity and molecular mimicry in defining anti-HER-2/neu MAb-3 linear peptide epitope. Peptides. 24: 193-197, 2003.
27. Mittelman A, Tiwari R, Lucchese G, Willers J, Dummer R, and Kanduc D. Identification of monoclonal anti-HMW-MAA antibody linear peptide epitope by proteomic database mining. J. Invest. Dermatol. 123: 670-675, 2004.
28. Kanduc, D., Fanizzi, F.P., Lucchese, G., Stevanovic, S., Sinha, A.A, and Mittelman, A. NMR probing of in silico identification of anti-HPV16 E7 mAb linear peptide epitope. Peptides. 25: 243-250, 2004.
29. Dummer, R., Mittelman, A., Fanizzi, F.P., Lucchese, G., Willers, J., and Kanduc, D. Non-self-discrimination as a driving concept in the identification of an immunodominant HMW-MAA epitopic peptide sequence by autoantibodies from melanoma cancer patients. Int. J. Cancer. 111: 720-726, 2004.
30. Tiwari, R., Geliebter, J., Lucchese, A., Mittelman, A., and Kanduc, D. Computational peptide dissection of Melana/MART-1 oncoprotein antigenicity. Peptides. 25: 1865-1871, 2004.
31. Shoenfeld, Y., and Gershwin, M.E. Cancer and autoimmunity. Elsevier, 2000.
32. Gilboa, E. The risk of autoimmunity associated with tumor immunotherapy. Nat. Immun. 2: 789-792, 2001.
33. Anhalt, G.J., Kim, S.C., Stanley, J.R., Korman, N.J., Jabs, D.A., Kory, M., Izumi, H., Ratrie, H. 3rd, Mutasim, D., Ariss-Abdo, L., et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N. Engl. J. Med. 323: 1729-1735, 1990.
34. Amagai, M., Klaus-Kovtun, V., and Stanley, J.R. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 67: 869-877, 1991.
35. Futei, Y., Amagai, M., Hashimoto, T., and Nishikawa, T. Conformational epitope mapping and IgG subclass distribution of desmoglein 3 in paraneoplastic pemphigus. J. Am. Acad. Dermatol. 49: 1023-1028, 2003.
36. Lucchese, A., Mittelman, A., Lin, M.S., Kanduc, D., and Sinha, A.A. Epitope definition by proteomic similarity analysis: identification of the linear determinant of the anti-Dsg3 MAb 5H10. J. Transl. Med. 2: 43, 2004.
37. Harlow, E., and Lane, D. Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1988.
38. Hacker-Foegen, M.K., Janson, M., Amagai, M., Fairley, J.A., and Lin, M.S. Pathogenicity and epitope characteristics of anti-desmoglein-1 from pemphigus foliaceus patients expressing only IgG1 autoantibodies. J. Invest. Dermatol. 121: 1373-1378, 2003.
39. Schenk, D. Opinion: amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3: 824-828, 2002.
40. Janssen, E.M., van Oosterhout, A.J., van Rensen, A.J., van Eden, W., Nijkamp, F.P., and Wauben, M.H. Modulation of Th2 responses by peptide analogues in a murine model of allergic asthma: amelioration or deterioration of the disease process depends on the Th1 or Th2 skewing characteristics of the therapeutic peptide. J. Immunol. 164: 580-588, 2000.